PMID- 17542749
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20211103
IS  - 1744-8395 (Electronic)
IS  - 1476-0584 (Linking)
VI  - 6
IP  - 3
DP  - 2007 Jun
TI  - Optimizing dendritic cell-based immunotherapy for cancer.
PG  - 333-45
AB  - Dendritic cells (DCs) are the most powerful professional antigen-presenting cells 
      and are unique in their capability to initiate, maintain and regulate the 
      intensity of primary immune responses, including specific antitumor responses. 
      Development of practical procedures to prepare sufficient numbers of functional 
      human DCs in culture from the peripheral blood precursors, paved the way for 
      clinical trials to evaluate various DC-based strategies in patients with 
      malignant diseases. However, no definite conclusions regarding the clinical and 
      even immunological efficacy of DC vaccination can be stated, despite the fact 
      that 12 years have passed since the first clinical trial utilizing DCs in cancer 
      patients. Many unanswered questions hamper the development of DC-based vaccines, 
      including the source of DC preparation and protocols for DC generation, 
      activation and loading with tumor antigens, source of tumor antigens, route of 
      vaccine administration and methods of immunomonitoring. Fortunately, in spite of 
      the many obstacles, DC vaccines continue to hold promise for cancer therapy.
FAU - Zhong, Hua
AU  - Zhong H
AD  - Shanghai Jiao Tong University, Shanghai Chest Hospital, 241 Huaihai Road (w), 
      Shanghai 200030, China. harriet_zhong@hotmail.com
FAU - Shurin, Michael R
AU  - Shurin MR
FAU - Han, Baohui
AU  - Han B
LA  - eng
GR  - 2R01 CA84270/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Cancer Vaccines/administration & dosage/immunology/*therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy, Active/*methods
MH  - Neoplasms/*immunology/*therapy
EDAT- 2007/06/05 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/06/05 09:00
PHST- 2007/06/05 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/06/05 09:00 [entrez]
AID - 10.1586/14760584.6.3.333 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2007 Jun;6(3):333-45. doi: 10.1586/14760584.6.3.333.